Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Chengdu Hoist Wins Approval for Liver Cancer Drug

publication date: Jun 8, 2007
Drug Combines Monoclonal Antibody and Radioactive Iodine -- Chengdu Hoist Inc. Ltd. received the State Food and Drug Administration's approval to begin marketing a new treatment for hepatocellular (liver) cancer. The drug is an iodine (131I) metuximab injection that is indicated for patients whose liver cancer cannot be operated on or who have relapsed following earlier therapies.Chengdu Hoist received new drug approval, production approval and a GMP certificate from the State Food and Drug Administration at the end of 2006. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital